Журнал инфектологии (Oct 2018)

RESULTS OF THE USE OF SOFOSBUVIR IN COMBINATION WITH LEDIPASVIR OR DACLATASVIR FOR CHRONIC HEPATITIS C TREATMENT IN THE REPUBLIC OF BELARUS

  • S. V. Zhavoronok,
  • V. R. Gutmane,
  • T. M. Baryash,
  • O. V. Soldatenko,
  • T. V. Znovets,
  • V. M. Mitsura,
  • E. V. Voropaev,
  • E. L. Gasich,
  • E. N. Yagovdik-Telezhnaja,
  • L. V. Sivachenko,
  • L. A. Anisko,
  • L. S. Zhmurovskaja,
  • S. V. Krapivina,
  • N. N. Yurovskij,
  • I. V. Yurkevich,
  • I. A. Karpov

DOI
https://doi.org/10.22625/2072-6732-2018-10-3-77-83
Journal volume & issue
Vol. 10, no. 3
pp. 77 – 83

Abstract

Read online

To evaluate the efficacy of therapy with sofosbuvir in combination with ledipasvir or daclatasvir, the results of treatment of 299 patients with chronic hepatitis C, including 128 non-responders to combined interferon plus ribavirin therapy, who have prognostically unfavorable single nucleotide polymorphisms 39743165T> G (rs8099917) and 39738787C> T (rs12979860) of interleukin-28B gene, were analyzed. 57 people had liver cirrhosis. 80,9% (242) had genotype 1 of hepatitis C virus, 5% (15) – genotype 2, 13,7% (41) – genotype 3, and 0,4% (1) – genotype 4.All 299 patients, who adhered to the recommendations of the European Association for the Study of the Liver 2016 and the American Association for the Study of the Liver Disease 2017, achieved a sustained virologic response 12 weeks after the end of therapy. The clinical case of treatment failure, associated with the lack of confirmation of the elimination of hepatitis C virus by means of highly sensitive polymerase chain reaction methods and with the later identified amino acid substitution in position Y93H of NS5A (resistance to NS5A inhibitors), is shown.It is necessary to carry out monitoring of effectiveness of therapy only by means of highly sensitive polymerase chain reaction (from 10 ME/ml). If the virus elimination delays in patients with advanced stages of liver fibrosis it is needed to use the prolonged schemes of treatment. Repeated treatment of patients with existence of a mutation of Y93H requires the use of new NS5A inhibitors or combined drugs.

Keywords